|Bid||0.1000 x 0|
|Ask||0.1000 x 0|
|Day's Range||0.1000 - 0.1100|
|52 Week Range||0.0300 - 0.1600|
|Beta (5Y Monthly)||2.73|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
VANCOUVER, BC, March 22, 2021 /CNW/ - The following issues have been halted by IIROC: Company: iCo Therapeutics Inc.TSX-Venture Symbol: ICO All Issues: YesReason: At the Request of the Company Pending NewsHalt Time (ET): 7:46 AMIIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company.
Vancouver, British Columbia--(Newsfile Corp. - March 22, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo") and Satellos Bioscience Inc. ("Satellos"), a private Canadian corporation, together are pleased to announce the execution of a definitive agreement, dated March 21, 2021 (the "Arrangement Agreement"), providing for the business combination of iCo and Satellos by way of a plan of arrangement (the "Arrangement") in accordance with Section 192 of the Canada Business Corporations Act (the ...
Vancouver, British Columbia--(Newsfile Corp. - March 15, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") announced that its wholly owned subsidiary, Amphotericin B Technologies, Inc., has entered into an agreement with IIT Research Institute to test the in vivo efficacy of iCo's novel oral amphotericin B asset ("iCo-019") against SARS-CoV-2, the causative agent of COVID-19 in the hACE2 mouse model (the "iCo-019 Study"). iCo anticipates that the iCo-019 ...